Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAKEI V carboplatin versus cisplatin trial in extracranial malignant germ cell tumors
NL-OMON51290Phase 3Recruiting
- Sponsor
- University of Bonn
- Start
- Feb 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin and cisplatin in germ cell tumor (GCT) and Germ Cell Carcinoma, sponsored by University of Bonn. Primary endpoint: Randomized event-free survival. Started Feb 2024; status: recruiting.
02
Drugs
carboplatincisplatin
03
Conditions
germ cell tumor (GCT)Germ Cell Carcinoma
Beyond the preview
Go deeper on NL-OMON51290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51290.